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Abstract 
Background: The Tanzanian National Malaria Control Programme (NMCP) and its partners have been implementing 
regular therapeutic efficacy studies (TES) to monitor the performance of different drugs used or with potential use in 
Tanzania. However, most of the recent TES focused on artemether–lumefantrine, which is the first-line anti-malarial for 
the treatment of uncomplicated falciparum malaria. Data on the performance of other artemisinin-based combina-
tions is urgently needed to support timely review and changes of treatment guidelines in case of drug resistance to 
the current regimen. This study was conducted at two NMCP sentinel sites (Kibaha, Pwani and Ujiji, Kigoma) to assess 
the efficacy and safety of artesunate–amodiaquine (ASAQ) and dihydroartemisinin–piperaquine (DP), which are the 
current alternative artemisinin-based combinations in Tanzania.
Methods: This was a single-arm prospective evaluation of the clinical and parasitological responses of ASAQ and 
DP for directly observed treatment of uncomplicated falciparum malaria. Children aged 6 months to 10 years and 
meeting the inclusion criteria were enrolled and treated with either ASAQ or DP. In each site, patients were enrolled 
sequentially; thus, enrolment of patients for the assessment of one artemisinin-based combination was completed 
before patients were recruited for assessment of the second drugs. Follow-up was done for 28 or 42 days for ASAQ 
and DP, respectively. The primary outcome was PCR corrected cure rates while the secondary outcome was occur-
rence of adverse events (AEs) or serious adverse events (SAEs).
Results: Of the 724 patients screened at both sites, 333 (46.0%) were enrolled and 326 (97.9%) either completed the 
28/42 days of follow-up, or attained any of the treatment outcomes. PCR uncorrected adequate clinical and parasito-
logical response (ACPR) for DP on day 42 was 98.8% and 75.9% at Kibaha and Ujiji, respectively. After PCR correction, 
DP’s ACPR was 100% at both sites. For ASAQ, no parasite recurrence occurred giving 100% ACPR on day 28. Only one 
patient in the DP arm (1.1%) from Ujiji had parasites on day 3. Of the patients recruited (n = 333), 175 (52.6%) had 
AEs with 223 episodes (at both sites) in the two treatment groups. There was no SAE and the commonly reported AE 
episodes (with > 5%) included, cough, running nose, abdominal pain, diarrhoea and fever.
Conclusion: Both artemisinin-based combinations had high cure rates with PCR corrected ACPR of 100%. The two 
drugs had adequate safety with no SAE and all AEs were mild, and not associated with the anti-malarials. Continued 
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Background
A substantial decline in malaria incidence, over 20% 
between 2010 and 2015, was observed in the past dec-
ade [1]. However, the most recent reports showed an 
increase in malaria incidence in 2016 and 2017, which 
might reverse the achievements attained in the past two 
decades [2, 3]. Malaria is still responsible for more than 
435,000 deaths and over 219 million cases, with > 90% of 
the deaths and cases from sub-Saharan Africa (major-
ity being under-fives and pregnant women) [3]. Despite 
a significant decline of malaria morbidity and mortality 
between 2000 and 2015 (> 18 million cases and > 100,000 
deaths in 2000s) [4], Tanzania is still among the 10 high 
burden countries in Africa, with about 5.8 million cases 
and < 4000 deaths reported in 2017 [3].
Improved case management which involves early 
diagnosis (by microscopy or rapid diagnostic tests) and 
prompt treatment with effective anti-malarials is one 
of the current effective strategies to fight malaria [3]. 
Artemisinin-based combination therapy (ACT) recom-
mended by the World Health Organization (WHO) is 
effective for the treatment of uncomplicated falcipa-
rum malaria and replaced monotherapies due to wide-
spread resistance to previously used drugs [5]. Effective 
case management using ACT is believed to have sig-
nificantly contributed to the recent reduction in malaria 
burden [1, 3]. Currently, the WHO recommends five 
artemisinin-based combinations for the treatment of 
uncomplicated falciparum malaria and these include 
artemether–lumefantrine (AL), artesunate–amodiaquine 
(ASAQ), artesunate-mefloquine (AS + MQ), dihydroar-
temisinin–piperaquine (DP) and artesunate-sulfadoxine/
pyrimethamine (AS + SP) [6]. Pyronaridine–artesunate is 
another artemisinin-based combination which has been 
shown to have high therapeutic efficacy and safety for 
the treatment of uncomplicated malaria caused by Plas-
modium falciparum and other species, and it will poten-
tially offer an additional effective anti-malarial drug on 
top of the current ACT formulations [7–9]. Of these, AL 
is the commonly used ACT as the first-line anti-malarial 
for the treatment of uncomplicated malaria in most of 
malaria endemic countries, especially in the WHO Afri-
can region followed by ASAQ [10]. Most of these arte-
misinin-based combinations still have high cure rates 
particularly in Africa [14–28], despite recent reports of 
artemisinin resistance and treatment failure with ACT in 
Southeast Asia (SEA) [11–16].
Due to high level of parasite resistance to SP and fol-
lowing WHO recommendations, Tanzania introduced 
AL as first-line drug for the treatment of uncompli-
cated malaria in 2006 [17]. Studies conducted in Tan-
zania before and after changes of the malaria treatment 
guidelines showed that AL is safe and efficacious (PCR 
corrected cure rate of > 95% by D28) [18–21]. However, 
confirmation of P. falciparum resistance to artemisinins 
[11, 13, 14] and other key partner drugs including pipe-
raquine [22] in SEA, which was the epicentre for the evo-
lution and spread of resistance to all important classes of 
anti-malarials, indicates that resistance to the currently 
recommended anti-malarial medicines could follow a 
similar mechanism and dispersal pattern [23]. Thus, the 
WHO recommends that regular surveillance to monitor 
efficacy and safety of ACT should be undertaken (bien-
nial) by all malaria endemic countries in order to ensure 
optimum case management and facilitate early detection 
of emergence of artemisinin and partner drug resistance 
[24].
The Tanzania National Malaria Control Programme 
(NMCP), together with its partners, has been and are 
continuously implementing therapeutic efficacy stud-
ies (TES) to monitor the efficacy and safety of different 
anti-malarials including ACT that are being used or with 
potential future use in the country. The studies are con-
ducted at eight sentinel sites located in regions with dif-
ferent malaria transmission intensities and also covering 
border areas, with high potentials of introducing para-
sites from neighbouring countries [25, 26]. These and 
previous studies which tested different anti-malarials in 
Tanzania [18], provided important evidence of the effi-
cacy and safety of anti-malarials, and the data generated 
was used to support changes of malaria treatment guide-
lines to replace chloroquine with SP in 2001 [27] and AL 
to replace SP in 2006 [17]. Most of the recent studies 
focused on AL, which is the first line anti-malarial for the 
treatment of uncomplicated malaria in mainland Tan-
zania ([20], and Ishengoma et al. pers. commun.). How-
ever, data on the performance of other ACT is scanty [19, 
20] and urgently needed to support timely review and 
changes of treatment guidelines in case of emergence of 
drug resistance to the current regimen. With confirmed 
TES is critical to monitor the performance of nationally recommended artemisinin-based combination therapy and 
supporting evidence-based review of malaria treatment policies.
Trial registration This study is registered at ClinicalTrials.gov, No. NCT03431714
Keywords: Efficacy, Safety, Artesunate–amodiaquine, Dihydroartemisinin–piperaquine, Plasmodium falciparum, 
Tanzania
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resistance to artemisinins [11, 13, 14] and piperaquine in 
SEA [22], it is critical to ensure that studies to assess the 
efficacy and safety of other ACT are conducted in Tan-
zania. The current study was conducted at two NMCP 
sentinel sites to assess the efficacy and safety of ASAQ 
and DP for the treatment of uncomplicated malaria. Of 
these, ASAQ is the first-line anti-malarial in Zanzibar, 
and DP was recently introduced in Tanzania as an alter-
native ACT for the treatment of uncomplicated falcipa-
rum malaria, in order to improve case management when 
indicated or in case AL is out of stock [28].
Methods
Study sites
This study was carried out between July and December 
2017 at Kibaha and Ujiji sites, which are among the 8 
NMCP sentinel sites for monitoring anti-malarial efficacy 
in Tanzania [25, 26] (Fig. 1). The study was conducted at 
Magindu dispensary in Kibaha district in Coastal (Pwani) 
region, located about 100  km west of Dar es Salaam. 
Kibaha is currently characterized as a low malaria trans-
mission site with prevalence among under-fives ranging 
from 5 to 10% in 2017 [29].
Fig. 1 Map of Tanzania showing the two NMCP sentinel sites marked with red triangles
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The second study site was Ujiji health centre which is 
located in the district of Kigoma urban in Kigoma region, 
north-western Tanzania. Despite high variability, the 
entire region of Kigoma is considered to be an area of 
high burden of malaria with parasite prevalence among 
under-fives ranging from 26% between 2012 and 2016 
[30–32] to more than 43% in 2017 [29] and Chiduo et al. 
(pers. commun.). Further description of Ujiji site and 
Kigoma urban district was provided elsewhere [33].
Study design and target population
This was a single-arm prospective study that assessed the 
therapeutic efficacy and safety of ASAQ and DP for the 
treatment of uncomplicated falciparum malaria. Children 
aged between 6  months to 10  years and attending the 
outpatients departments (OPDs) of the two health facili-
ties were screened for possible inclusion in the study. 
Patients were first enrolled in the DP group between July 
and September 2017, until the sample size was attained 
before enrolment for ASAQ was initiated (September to 
November 2017). Enrolled patients were followed-up for 
28 (ASAQ) or 42 days (DP) as per the WHO protocol of 
2009 [24].
Sample size estimation
The sample size was determined based on WHO stand-
ard protocol [24], with the assumption that 5% of the 
patients were likely to have a treatment failure after treat-
ment with either of the two ACT. At a confidence level of 
95% and an estimated precision of 5%; a minimum sam-
ple size was 73 patients in each treatment group at each 
of the two sites of Kibaha and Ujiji. The sample size was 
increased by 20% to allow for loss to follow-up and with-
drawals during the 28 or 42-day follow-up for ASAQ and 
DP, respectively. The final sample size was 88 patients per 
drug per site and 352 for both drugs.
Screening and recruitment of study participants
Children presenting to OPDs with age ranging between 
6 months to 10 years and fever at presentation (axillary 
temperature ≥ 37.5 °C) or reported history of fever in the 
last 24 h were screened for possible enrolment, as previ-
ously described [33]. Recruitment of study participants at 
both sites was done starting with DP first followed with 
ASAQ. Once the sample size for DP was reached enrol-
ment for ASAQ started. Since the study was undertaken 
in areas that have transitioned from high to moderate/
low malaria transmission, older children (up to 10 years) 
were also enrolled and parasitaemia was adjusted to 
include those with 250–200,000 asexual parasites per 
microlitre of blood. Other inclusion and exclusion crite-
ria were as per WHO protocol of 2009 [24], and as previ-
ously described [18–20].
Laboratory examination
Laboratory screening involved a finger prick to obtain 
a blood sample for quick detection of malaria para-
sites using rapid diagnostic tests (RDTs) and collection 
of thick and thin blood smears for microscopy [33]. For 
patients with positive RDT results, two blood slides were 
collected and one of the slides was stained with 10% 
Giemsa for 10–15  min and examined by microscopy to 
detect presence of malaria parasites and the level of para-
sitaemia. The second blood slide was stained with 3% 
Giemsa for 30–45 min and used to determine the actual 
parasite density, species and presence of gametocytes. 
Detection of malaria parasites, parasite count and quality 
control of blood smears were undertaken as previously 
described [18, 19].
From each patient, dried blood spots (DBS) on filter 
papers (Whatmann No. 3, GE Healthcare Life Sciences, 
PA, USA) were collected for PCR genotyping to distin-
guish recrudescent from new infections. Extraction of 
parasite DNA from DBS was done at the laboratory 
in Tanga using QIAamp DNA blood mini kit (Qiagen 
GmbH, Hilden, Germany) according to the manufac-
turer’s instructions. Genotyping of paired samples (day 
0 and parasites collected on or after day 14) was done 
by analysis of the highly polymorphic loci of merozoite 
surface proteins 1 and 2 (msp1 and msp2), and glutamate 
rich protein (glurp) genes to distinguish true recrudes-
cence from re-infection as previously described [24, 34].
Treatment and follow‑up
Patients enrolled in the study were treated with either 
ASAQ  (Winthrop®, Sanofi Aventis, Morocco) or DP 
(Duo-Cortecxin®, Holley-Cotec Pharmaceuticals, China) 
obtained from WHO. The co-formulated ASAQ tablets 
contained 25  mg or 67.5  mg of artesunate and 50  mg 
or 135  mg amodiaquine in a tablet. DP was also a co-
formulated regimen with tablets containing 40  mg and 
320  mg of dihydroartemisinin and piperaquine, respec-
tively. The drugs were administered according to the rec-
ommended doses based on body weight of patients. For 
ASAQ (25/67.5 mg), 1 tablet was given to children weigh-
ing < 10  kg; and for the 50/135  mg tablets, 1 tablet was 
given to those with 10–20 kg; 2 tablets to children with 
21–30 kg and 3 tablets to children weighing > 30 kg. DP 
(40/320 mg) was administered with a quarter, half, a full 
tablet or 2 tablets given to patients weighing 5 to < 7 kg, 7 
to  < 13 kg, 13 to  < 24 kg and 24 to  < 36 kg, respectively. 
A full course of either ASAQ or DP consisted of 3 doses 
given once daily after every 24 h. Patients were observed 
for 30  min to ensure that they did not vomit the study 
drugs. When vomiting occurred, a repeat dose was given 
after vomiting stopped. Any patient who persistently 
vomited the study medication was withdrawn and treated 
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with intravenous quinine or intramuscular artesunate 
according to the national guidelines for management of 
severe malaria [17]. Paracetamol was given to all patients 
with body temperature greater than or equal to 38 °C. All 
doses of the study drugs were administered orally under 
direct observation of a study nurse.
Scheduled follow-up visits were done on days 1, 2, 3, 7, 
14, 21 and 28 for ASAQ or with 2 extra visits on 35 day 
and 42 for DP; or at any other time (unscheduled visits) 
when patients felt unwell. Parents/guardians were asked 
to bring their children to the clinic at any time when they 
felt unwell without waiting for scheduled visits or taking 
them to other health facilities for medical attention. All 
patients who failed to turn up for their scheduled visits 
by mid-day were followed-up at their respective homes 
by a member of the study team and asked to come to the 
health centre for their visits. Patients who travelled away 
from the centre and could not be traced, were classified 
as lost and withdrawn from the study. During the visits, 
both clinical and parasitological assessments were per-
formed; and follow-up samples (blood slides and DBS) 
were also collected.
Safety assessment
Both passive and active methods were used to assess the 
safety of the two drugs through interviews with parents/
guardian to capture and report adverse events (AEs) or 
serious adverse events (SAEs). Parents/guardian were 
interviewed at each visit and asked to report any occur-
rence and nature of AE or SAE that occurred at home 
between follow-up visits. At the study facilities, clini-
cal examination and/or laboratory tests were also used 
to determine and capture AEs and SAEs. The captured 
events were recorded on case report forms for each fol-
low-up visit. An AE or SAE were defined and classified 
according to WHO protocol [24]. Reporting procedures 
for any SAE included submission of a written report by 
the principal investigator to the sponsor (the National 
Institute for Medical Research—NIMR), NMCP and the 
Tanzanian Medical Research Coordinating Committee 
(MRCC) of NIMR (which is the national ethics review 
board in Tanzania). Reporting of an SAE was done within 
24  h of occurrence regardless of whether the principal 
investigator considered the event to be related to the 
investigated drug or not. Patients with AEs or SAEs were 
thoroughly assessed and managed accordingly, and the 
events were also assessed to determine their association 
with the study drugs.
Outcome classification
The primary end point was parasitological cure on 
day 28 for ASAQ and day 42 for DP as per WHO pro-
tocol of 2009 [24], while secondary end points included 
parasitaemia on day 3 and occurrence of AEs/SAEs. The 
primary treatment outcomes were classified as early 
treatment failure (ETF), late clinical failure (LCF), late 
parasitological failure (LPF), and adequate clinical and 
parasitological response (ACPR) before and after PCR 
correction [24]. Rescue treatment for recurrent infections 
identified during follow-up was done using artemether–
lumefantrine while patients with severe malaria were 
managed with intravenous quinine or intramuscular 
artesunate.
Ethical considerations
The protocol was reviewed and approved by the MRCC 
of NIMR and permission to conduct the study at the 
health facilities was sought in writing from the relevant 
regional and district medical authorities. Oral and writ-
ten informed consent was obtained from parents or 
guardians of all eligible patients before their children 
were screened for possible inclusion into the study. Infor-
mation about the study protocol, inclusion criteria, fol-
low-up schedule, and benefits and risks of participating 
in the study was provided to parents/guardians during 
the consenting process. The study is registered at Clini-
calTrials.gov, No. NCT03431714.
Data management and analysis
Single entry was concurrently performed at the study 
sites during data collection while the second entry was 
done by another data entry clerk after the end of field-
work. The data were entered into a Microsoft Access 
database accessible online via internet, and was later 
validated, cleaned and analysed using STATA for Win-
dows, version 13 (STATA Corporation, TX-USA). The 
data were also transferred to the WHO Excel software 
programme [35], for automatic analysis of treatment out-
comes. Descriptive statistics such as percentages, mean, 
median, standard deviation, and range were reported as 
appropriate. Treatment outcomes were analysed based 
on per protocol method and Kaplan–Meier analysis and 
reported as uncorrected and PCR corrected cure rates. 
Baseline characteristics, primary and secondary out-
comes were compared between the two sites for each 
drug. Continuous variables such as  log10 transformed 
parasite density (at enrolment) and age of patients 
from the two sites were compared using t test (for nor-
mally distributed data) or Mann–Whitney U test (a 
non-parametric test for non-normally distributed data). 
Distinguishing recrudescent from new infections was 
done using msp2 followed by glurp and msp1 based on 
the WHO protocol [24, 34]. Inconclusive results were 
reported as non-determined and excluded from the 
analysis of treatment outcomes. For all statistical tests, 
p-value of < 0.05 was considered to be significant.
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Results
Baseline characteristics
A total of 724 patients were screened at both sites, 333 
(46.0%) were enrolled into the study and 326 (97.9%) 
completed the follow-up visits or had an assigned treat-
ment outcome (Figs.  2 and 3). There was no signifi-
cant difference in age (p = 0.097), axillary temperature 
(p = 0.216) and sex (p = 0.946) of patients recruited at the 
2 sites (Table  1). Children recruited at Kibaha had sig-
nificantly higher weight (p = 0.003) and height (p < 0.001) 
compared to those from Ujiji. In addition, geometric 
mean parasite density was significantly higher at Ujiji 
than Kibaha (p = 0.013) (Table 1).
Treatment outcomes
Three patients (0.9%) were lost to follow-up at both 
sites while four (1.2%) (two from each site in the DP 
group) were withdrawn from the study for different 
reasons (Fig. 2 and Tables 2, 3). A total of 326 (97.9%) 
patients attained the study outcomes and were used 
in per protocol analysis, while in the Kaplan–Meier 
analysis; patients lost to follow-up and those with-
drawn were included in the analysis until the last day 
seen. Before PCR correction (on day 42), 1 (1.2%) and 
15 (18.1%) patient in the DP group at Kibaha and Ujiji, 
respectively, had LPF while 5 (6.0%) patients in the 
DP group from Ujiji site had LCF. For DP, PCR uncor-
rected ACPR of 98.8% (85/86) was reported at Kibaha 
on day 28 while it was 100% at Ujiji (Table 2). On day 
42, PCR uncorrected ACPR of DP was 98.8 (85/86) 
and 75.9% (63/83) at Kibaha and Ujiji, respectively 
(Table  3). After PCR correction, all recurrent infec-
tions in the DP group from both sites were new infec-
tions and PCR corrected ACPR was 100.0% (Tables  2 
and 3). For ASAQ, there was no treatment failure in 
both sites and the PCR uncorrected ACPR on day 28 
was 100.0% (Table 2). Only one patient in the DP arm 
(1.1%) from Ujiji had parasites on day 3 (Tables 2 and 
3).
Safety outcomes
Among the patients recruited in this study (n = 333), 175 
(52.6%) had one or more events of AEs, with 223 episodes 
of AEs at both sites. The commonly reported AE episodes 
included cough (39.0%), running nose (14.8%), abdomi-
nal pain (7.2%), diarrhoea (7.2%), fever (6.7%), vomiting 
(4.0%), skin itching (3.1%), painful micturition (2.7%), 
painful ear (2.7%), difficulty in breathing (2.2%) and oth-
ers (Table 4). Other AEs (n = 23) included 4 events each 
of headache, painful swallowing and mouth sore; three 
events were reported for loss of appetite and painful eyes; 
Fig. 2 Trial profile for ASAQ showing the flow of patients during screening, enrolment and follow-up
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Fig. 3 Trial profile for DP showing the flow of patients during screening, enrolment and follow-up
Table 1 Baseline characteristics of children enrolled at Kibaha and Ujiji
°C, degree Celsius; SD, standard deviation; GMPD, Geometric mean parasite density; pf, Plasmodium falciparum; 95% CI, 95% confidence interval; n, number of 
patients; IQR, Inter quartile range; µl, microlitre; ETF, early treatment failure; LCF, late clinical failure; LPF, late parasitological failure; ACPR, adequate clinical and 
parasitological response; PP, number of patients involved in the per protocol analysis; LFU, lost to follow-up; WD, withdrawn; n, number of episodes
* p = 0.013, ** p = 0.003, *** p < 0.001
Variable Study sites Overall
Kibaha Ujiji
DP ASAQ DP ASAQ
Screened 144 101 191 288 724
Enrolled 88 (61.1) 69 (68.3) 88 (46.1) 88 (30.6) 333 (46.0)
Age in years, mean (SD) 5.5 (2.8) 5.0 (2.7) 4.8 (2.6) 4.7 (2.8) 5.0 (2.7)
Gender (male), n (%) 54 (61.4) 34 (49.3) 45 (51.1) 53 (63.2) 186 (55.7)
Weight (kg), median 
(IQR)**
17 (13.3–21) 15 (12.5–22) 14 (12–18) 14.6 (11–18.5) 15 (12–19)
Height in cm, median 
(IQR)***
109 (93–123) 104 (92.5–121) 101 (83–112) 101 (86–115) 104 (90–119)
Body temp (°C) ± mean 
(SD)
37.9 (1.2) 37.8 (1.1) 38.2 (1.3) 38.0 (1.4) 38.0 (1.2)
Parasitaemia-GMPD 
(asexual pf/µl) 95% CI*
24,974 (18,822–33,136) 24,441 (16,166–36,954) 36,726 (27,481–49,082) 36,137 (28,809–45,329) 30,357 (26,157–35,231)
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and one event each of chicken pox, common cold, anae-
mia, blood in stool and visible worms. No case of SAE 
was reported at the two sites and all AEs were managed 
accordingly.
Discussion
This study was conducted to assess efficacy and safety of 
ASAQ and DP which are alternative ACT in Tanzania 
in order to provide data that will potentially support the 
review process and formulation of new treatment guide-
lines in case of resistance to the current anti-malarials. 
The findings showed high efficacy of ASAQ and DP at 
both sites, where the cure rate of ASAQ (PCR uncor-
rected ACPR = 100%) was higher compared to what was 
reported in other studies done in both Mainland Tanza-
nia and Zanzibar [36–38]. The cure rate of ASAQ was 
also higher compared to previous studies from other 
East African countries [39–44] and across Africa [45, 
46]. These results could possibly be due to resumption 
of parasite sensitivity to amodiaquine after it was with-
drawn in 2006 when the interim treatment guidelines 
of 2001 (which had SP as first-line and amodiaquine as 
the second-line anti-malarial) were changed to introduce 
ACT [17].
Previous studies conducted in Tanzania before and 
after the 2006 policy changes showed low PCR cor-
rected cure rates among patients treated with ASAQ 
which ranged from 88 to 94% [18] and this was possi-
bly due to high resistance to amodiaquine monotherapy 
[38, 47, 48]. Furthermore, studies conducted in Tanzania 
and other countries in SSA showed high treatment fail-
ure to amodiaquine which is a partner drug in the ASAQ 
combination [18, 39, 41, 43–46, 49]. Thus, withdrawal of 
amodiaquine monotherapy and introduction of AL could 
Table 2 Treatment outcomes before and after PCR genotyping on day 28
Item Kibaha Ujiji Total
Outcome DP (n = 88) ASAQ (n = 69) DP (n = 88) ASAQ (n = 88) N = 333
PCR uncorrected
 Day 3 parasitaemia 0 (0.0%) 0 (0.0%) 1 (1.1%) 0 (0.0%) 1 (0.3%)
 ETF 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
 LPF 1 (1.2%) 0 (0) 0 (0.0%) 0 (0) 1 (0.3%)
 LCF 0 (0) 0 (0) 0 (0.0%) 0 (0) 0 (0.0%)
 ACPR 85 (98.8%) 69 (100%) 83 (100%) 88 (100%) 325 (99.6%)
 Total PP 86 69 83 88 326
 LFU 0 (0%) 0 (0%) 3 (3.4%) 0 (0%) 3 (0.9%)
 WD 2 (2.3%) 0 (0%) 2 (2.3%) 0 (0%) 4 (1.2%)
PCR corrected
 ETF 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
 LPF 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
 LCF 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
 ACPR 85 (100%) 69 (100%) 83 (100%) 88 (100%) 325 (100%) 
 Total PP 85 69 83 88 325
 LFU 0 (0.0%) 0 (0%) 3 (3.4%) 0 (0.0%) 3 (0.9%)
 WD 2 (2.3%) 0 (0.0%) 2 (2.3%) 0 (0.0%) 4 (1.2%)
Table 3 Treatment outcomes for  DP before  and  after PCR 
genotyping on day 42
Item Kibaha Ujiji Total
Outcome DP (n = 88) DP (n = 88) N = 176
PCR uncorrected
 Day 3 parasitaemia 0 (0.0%) 1 (1.1%) 1 (0.6%)
 ETF 0 (0.0%) 0 (0.0%) 0 (0.0%)
 LPF 1 (1.2%) 15 (18.1%) 16 (9.5%)
 LCF 0 (0) 5 (6.0%) 5 (3.0%)
 ACPR 85 (98.8%) 63 (75.9%) 148 (87.6%)
 Total PP 86 83 169
 LFU 0 (0%) 3 (3.4%) 3 (1.7%)
 WD 2 (2.3%) 2 (2.3%) 4 (2.3%)
PCR corrected
 ETF 0 (0.0%) 0 (0.0%) 0 (0.0%)
 LPF 0 (0.0%) 0 (0.0%) 0 (0.0%)
 LCF 0 (0.0%) 0 (0.0%) 0 (0.0%)
 ACPR 85 (100%) 63 (100%) 148 (100%) 
 Total PP 85 63 148
 LFU 0 (0.0%) 3 (3.4%) 3 (1.7%)
 WD 3 (3.4%) 22 (25.0%) 25 (7.5%)
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have resulted into restoration of amodiaquine sentistivity 
due to reduced drug pressure leading to high efficacy of 
ASAQ. However, studies have also showed that increased 
use of lumefantrine as a partner drug selects for parasites 
which are sensitive to both chloroquine and amodiaquine 
[23]. Further surveillance will be required to monitor the 
performance of ASAQ in areas such as Mainland Tanza-
nia where drug pressure caused by amodiaquine is con-
tinuously reduced by use of AL.
According to WHO, the proportion of patients with 
parasitaemia on day 3 post-treatment (day 3 positivity 
rate) should be reported as an important indicator for 
identifying suspected artemisinin partial resistance in P. 
falciparum [50]. In this study, all patients but one (99.7%) 
cleared parasites on day 3. This is consistent with stud-
ies done in Tanzania [15–18] and other African coun-
tries [51–53], further suggesting that partial resistance to 
artemisinin has not emerged in Tanzania. The high PCR 
corrected cure rate for DP in this study supports ear-
lier findings from Tanzania, whereby the PCR corrected 
cure rates ranging from 94.6 to 100% have been recently 
reported in Kyela, Muheza and Ujiji [19, 20]. Similarly, 
studies undertaken in the East African regions [51, 54–
56] and across Africa [57, 58] have reported high cure 
rates among patients with uncomplicated malaria treated 
with DP.
Although the current study reported day 42 PCR cor-
rected ACPR of 100%, a high rate of recurrent infec-
tion was also reported in the DP group at Ujiji and all 
occurred after day 28. PCR uncorrected ACPR of both 
drugs on day 28 was 100% and all recurrent infections in 
the DP group were confirmed to be new infections after 
PCR genotyping. This is a major concern for effective 
case management since previous studies involving other 
artemisinin-based combinations [18, 19] also reported 
higher rates of recurrent infections particularly in areas 
with high malaria transmission like Kigoma. In the previ-
ous studies, recurrent infections among patients treated 
with different artemisinin-based combinations (most of 
them were due to new infections) were attributed to high 
transmission of malaria in Kigoma and other sites where 
high prevalence among under-fives has been reported 
[29–32]. In Kigoma, a recent study also reported high 
density of Anopheles funestus (Chiduo et al., pers. com-
mun.), which is a highly potent malaria vector, suggest-
ing that more strategies and targeted malaria control 
interventions are urgently required to reduce the burden 
of malaria in this region. From the NMCP perspective, 
there is a need to ensure that preventive measures like 
insecticide-treated bed nets are made available and used 
by the population living in these areas.
This study also showed that the two drugs were well 
tolerated with minimal AEs and with no any SAE. Of the 
AEs, majority of the cases (39.0%) had episodes of cough 
and the rest had other mild symptoms. Studies con-
ducted in Tanzania [18, 20] and elsewhere in Africa [58] 
reported similar safety profile of ASAQ and DP when the 
drugs were used for the treatment of uncomplicated fal-
ciparum malaria.
Conclusion
This study showed that the two artemisinin-based com-
binations had high efficacy for the treatment of uncom-
plicated falciparum malaria with PCR corrected cure 
rate of 100% for both drugs. The drugs had adequate 
safety profile with no SAE and all the reported AEs 
were mild, and resolved on their own or after medical 
interventions. Further surveillance will be required to 
Table 4 Episodes of adverse events reported at Kibaha and Ujiji
n = number of episodes
AEs Kibaha Ujiji Total (n = 223)
DP (n = 73) ASAQ (n = 38) DP (n = 62) ASAQ (n = 50)
Cough 37 (50.7) 19 (50.0) 15 (24.2) 16 (32.0) 87 (39.0)
Running nose 15 (20.5) 3 (7.9) 7 (11.3) 8 (16.0) 33 (14.8)
Abdominal pain 4 (5.5) 2 (5.3) 6 (9.7) 4 (8.0) 16 (7.2)
Diarrhoea 2 (2.7) 1 (2.6) 7 (11.3) 6 (12.0) 16 (7.2)
Fever 3 (4.1) 1 (2.6) 8 (12.9) 3 (6.0) 15 (6.7)
Vomiting 3 (4.1) 0 (0) 3 (4.8) 3 (6.0) 9 (4.0)
Skin itching 3 (4.1) 1 (2.6) 3 (4.8) 0 (0) 7 (3.1)
Painful micturition 0 (0) 1 (2.6) 4 (6.5) 1 (2.0) 6 (2.7)
Painful ear 1 (1.4) 1 (2.6) 2 (3.2) 2 (4.0) 6 (2.7)
Difficulty in breathing 0 (0) 0 (0) 1 (1.6) 4 (8.0) 5 (2.2)
Others 5 (6.8) 9 (23.7) 6 (9.7) 3 (6.0) 23 (10.3%)
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assess the efficacy and safety of these alternative forms 
of ACT in order to support regular review of malaria 
treatment guidelines in Tanzania.
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